Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study
The article tells about prevention of ischemic stroke (IS) in patients after IS or transient ischemic attack (TIA) against a background of non-valvular atrial fibrillation (AF). Anticoagulation therapy variants for secondary IS prevention in AF are evaluated, such as vitamin K antagonist warfarin an...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2014-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/560 |
id |
doaj-809afc9bf26a4114902e7ed083d61c31 |
---|---|
record_format |
Article |
spelling |
doaj-809afc9bf26a4114902e7ed083d61c312021-07-28T13:29:17ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902014-12-010561110.21518/2079-701X-2014-5-6-11560Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF studyV. A. Parfyonov0S. V. Verbitskaya1First Moscow State Medical University named after I.M. SechenovFirst Moscow State Medical University named after I.M. SechenovThe article tells about prevention of ischemic stroke (IS) in patients after IS or transient ischemic attack (TIA) against a background of non-valvular atrial fibrillation (AF). Anticoagulation therapy variants for secondary IS prevention in AF are evaluated, such as vitamin K antagonist warfarin and novel oral anticoagulants: inhibitor of coagulation factor Xa rivaroxaban, apixaban, and the direct thrombin inhibitor dabigatran. There are results of a ROCKET AF subanalysis which compared rivaroxaban and warfarin in patients with AF after IS or TIA. It is noted that widespread clinical use of oral anticoagulants for atrial fibrillation could result in a significant reduction of IS morbidity and mortality in this country.https://www.med-sovet.pro/jour/article/view/560вторичная профилактика ишемического инсультафибрилляция предсердийпероральные антикоагулянтыапиксабандабигатранривароксабансубанализ исследования rocket afsecondary prevention of ischemic strokeatrial fibrillationoral anticoagulantsapixabandabigatranrivaroxabanrocket af subanalysis |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
V. A. Parfyonov S. V. Verbitskaya |
spellingShingle |
V. A. Parfyonov S. V. Verbitskaya Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study Медицинский совет вторичная профилактика ишемического инсульта фибрилляция предсердий пероральные антикоагулянты апиксабан дабигатран ривароксабан субанализ исследования rocket af secondary prevention of ischemic stroke atrial fibrillation oral anticoagulants apixaban dabigatran rivaroxaban rocket af subanalysis |
author_facet |
V. A. Parfyonov S. V. Verbitskaya |
author_sort |
V. A. Parfyonov |
title |
Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study |
title_short |
Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study |
title_full |
Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study |
title_fullStr |
Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study |
title_full_unstemmed |
Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study |
title_sort |
secondary ischemic stroke prevention in patients with atrial fibrillation: results of the rocket af study |
publisher |
Remedium Group LLC |
series |
Медицинский совет |
issn |
2079-701X 2658-5790 |
publishDate |
2014-12-01 |
description |
The article tells about prevention of ischemic stroke (IS) in patients after IS or transient ischemic attack (TIA) against a background of non-valvular atrial fibrillation (AF). Anticoagulation therapy variants for secondary IS prevention in AF are evaluated, such as vitamin K antagonist warfarin and novel oral anticoagulants: inhibitor of coagulation factor Xa rivaroxaban, apixaban, and the direct thrombin inhibitor dabigatran. There are results of a ROCKET AF subanalysis which compared rivaroxaban and warfarin in patients with AF after IS or TIA. It is noted that widespread clinical use of oral anticoagulants for atrial fibrillation could result in a significant reduction of IS morbidity and mortality in this country. |
topic |
вторичная профилактика ишемического инсульта фибрилляция предсердий пероральные антикоагулянты апиксабан дабигатран ривароксабан субанализ исследования rocket af secondary prevention of ischemic stroke atrial fibrillation oral anticoagulants apixaban dabigatran rivaroxaban rocket af subanalysis |
url |
https://www.med-sovet.pro/jour/article/view/560 |
work_keys_str_mv |
AT vaparfyonov secondaryischemicstrokepreventioninpatientswithatrialfibrillationresultsoftherocketafstudy AT svverbitskaya secondaryischemicstrokepreventioninpatientswithatrialfibrillationresultsoftherocketafstudy |
_version_ |
1721274616018632704 |